118 related articles for article (PubMed ID: 36680930)
21. Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival.
Helal DS; Darwish SA; Awad RA; Ali DA; El-Guindy DM
Diagn Pathol; 2023 Feb; 18(1):11. PubMed ID: 36737799
[TBL] [Abstract][Full Text] [Related]
22. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
[TBL] [Abstract][Full Text] [Related]
23. Uroplakin II as a single marker for luminal versus basal molecular subtypes in muscle invasive urothelial carcinoma.
Pryma C; Villamil C; Gibb EA; Oo HZ; Seiler R; Contreras-Sanz A; Douglas J; Black PC; Wang G
Virchows Arch; 2022 Sep; 481(3):397-403. PubMed ID: 35612672
[TBL] [Abstract][Full Text] [Related]
24. Fibroblast activation protein (FAP) expression in CK5/6 expressed (Basal subtype) & CK20 expressed (Luminal subtype) urothelial bladder carcinoma: an immunohistochemical study.
Hemida AS; Aiad HAES; Hassan NA; Al Sharaky DR
J Immunoassay Immunochem; 2022 Nov; 43(6):618-633. PubMed ID: 35787739
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.
Sikic D; Keck B; Wach S; Taubert H; Wullich B; Goebell PJ; Kahlmeyer A; Olbert P; Isfort P; Nimphius W; Hartmann A; Giedl J;
PLoS One; 2017; 12(6):e0179602. PubMed ID: 28632777
[TBL] [Abstract][Full Text] [Related]
26. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
27. Stratification of urothelial bladder carcinoma depending on immunohistochemical expression of GATA3 and CK5/6.
Serag Eldien MM; Abdou AG; Elghrabawy GRA; Alhanafy AM; Mahmoud SF
J Immunoassay Immunochem; 2021 Nov; 42(6):662-678. PubMed ID: 34106817
[TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort.
Weyerer V; Stoehr R; Bertz S; Lange F; Geppert CI; Wach S; Taubert H; Sikic D; Wullich B; Hartmann A; Eckstein M
World J Urol; 2021 Nov; 39(11):4011-4019. PubMed ID: 34259899
[TBL] [Abstract][Full Text] [Related]
29. A deep-learning workflow to predict upper tract urothelial carcinoma protein-based subtypes from H&E slides supporting the prioritization of patients for molecular testing.
Angeloni M; van Doeveren T; Lindner S; Volland P; Schmelmer J; Foersch S; Matek C; Stoehr R; Geppert CI; Heers H; Wach S; Taubert H; Sikic D; Wullich B; van Leenders GJ; Zaburdaev V; Eckstein M; Hartmann A; Boormans JL; Ferrazzi F; Bahlinger V
J Pathol Clin Res; 2024 Mar; 10(2):e12369. PubMed ID: 38504364
[TBL] [Abstract][Full Text] [Related]
30. Cytokeratin 20 expression is linked to stage progression and to poor prognosis in advanced (pT4) urothelial carcinoma of the bladder.
Bruch PG; Plage H; Hofbauer S; Kornienko K; Weinberger S; Roßner F; Schallenberg S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Zecha H; Klatte T; Schlomm T; Horst D; Elezkurtaj S
Exp Mol Pathol; 2023 Jun; 131():104860. PubMed ID: 36997051
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemistry subtyping of urothelial carcinoma is feasible in the daily practice.
Queipo FJ; Unamunzaga GM; Negro BF; Fuertes SG; Cortés MÁ; Tejedor EC; Mañas CMB; Ariño AB; Sjödahl G; Beorlegui C
Virchows Arch; 2022 Aug; 481(2):191-200. PubMed ID: 35731280
[TBL] [Abstract][Full Text] [Related]
32. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.
Guo CC; Dadhania V; Zhang L; Majewski T; Bondaruk J; Sykulski M; Wronowska W; Gambin A; Wang Y; Zhang S; Fuentes-Mattei E; Kamat AM; Dinney C; Siefker-Radtke A; Choi W; Baggerly KA; McConkey D; Weinstein JN; Czerniak B
Eur Urol; 2016 Oct; 70(4):611-620. PubMed ID: 26988609
[TBL] [Abstract][Full Text] [Related]
33. Impact of immunohistochemistry-based molecular subtype on predicting chemotherapy response and survival in patients with T1 stage bladder cancer after bladder-preserving treatment.
Lu J; Zhang Y; Wu C; Chu C; Liu Z; Cao Y
Jpn J Clin Oncol; 2021 Mar; 51(3):424-433. PubMed ID: 33319245
[TBL] [Abstract][Full Text] [Related]
34. Morphology, immunohistochemistry characteristics, and clinical presentation of microcystic urothelial carcinoma: a series of 10 cases.
Su W; Sui W; Cheng X; Zong Y; Qin Y; Cui F
Diagn Pathol; 2023 Aug; 18(1):94. PubMed ID: 37598154
[TBL] [Abstract][Full Text] [Related]
35. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification.
Yuk HD; Jeong CW; Kwak C; Kim HH; Moon KC; Ku JH
BMC Cancer; 2019 Sep; 19(1):897. PubMed ID: 31500577
[TBL] [Abstract][Full Text] [Related]
37. A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.
Patschan O; Sjödahl G; Chebil G; Lövgren K; Lauss M; Gudjonsson S; Kollberg P; Eriksson P; Aine M; Månsson W; Fernö M; Liedberg F; Höglund M
Eur Urol; 2015 Nov; 68(5):824-32; discussion 835-6. PubMed ID: 25770486
[TBL] [Abstract][Full Text] [Related]
38. Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer.
Bejrananda T; Kanjanapradit K; Saetang J; Sangkhathat S
Sci Rep; 2021 Oct; 11(1):21186. PubMed ID: 34707176
[TBL] [Abstract][Full Text] [Related]
39. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.
Zinnall U; Weyerer V; Compérat E; Camparo P; Gaisa NT; Knuechel-Clarke R; Perren A; Lugli A; Toma M; Baretton G; Kristiansen G; Wirtz RM; Cheng L; Wullich B; Stoehr R; Hartmann A; Bertz S
Hum Pathol; 2018 Oct; 80():55-64. PubMed ID: 29885409
[TBL] [Abstract][Full Text] [Related]
40. Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer.
Culpan M; Turan T; Ozkanli SS; Zenginkinet T; Kazan O; Ucar T; Atis G; Caskurlu T; Yildirim A
J Cancer Res Ther; 2021; 17(2):434-442. PubMed ID: 34121689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
